secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073502
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics reports 2025 net revenue $154.9M, up 7.4%; issues 2026 guidance $173-183M
--------------------------------------------------------------------------------

- Full-year 2025 net revenue $154.9M (+7.4% YoY); Q4 net revenue $40.6M (-0.5% vs Q4 2024).
- Acute care franchise grew 65.1% to $49.6M; ZYNRELEF +49%, APONVIE +156%.
- Oncology franchise declined 7.8% to $105.3M; CINVANTI -3.3%, SUSTOL -39.9%.
- 2026 guidance: net revenue $173-183M, adjusted EBITDA $10-20M.
- Cash $46.6M; ZYNRELEF J-code effective Oct 2025; prefilled syringe FDA target mid-to-late 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/0001193125-26-073502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526073502/hrtx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer